1. Novel Technologies for Target Delivery of Therapeutics to the Placenta during Pregnancy: A Review
- Author
-
Gerald J. Pepe and Eugene D. Albrecht
- Subjects
Spiral artery ,placenta ,Genetic enhancement ,Ischemia ,nonhuman primate ,Review ,QH426-470 ,Bioinformatics ,trophoblast-targeted nanoparticles ,Preeclampsia ,preeclampsia ,Pregnancy ,Placenta ,medicine.artery ,medicine ,Genetics ,Humans ,Uterine artery ,Genetics (clinical) ,peptide-mediated gene targeting ,Fetal Growth Retardation ,intra-placental gene therapy ,business.industry ,Uterus ,targeted placental VEGF gene therapy ,Genetic Therapy ,medicine.disease ,Placentation ,medicine.anatomical_structure ,pregnancy diseases ,Premature birth ,Liposomes ,Nanoparticles ,Female ,spiral artery remodeling ,Peptides ,business - Abstract
Uterine spiral artery remodeling is essential for placental perfusion and fetal growth and, when impaired, results in placental ischemia and pregnancy complications, e.g., fetal growth restriction, preeclampsia, premature birth. Despite the high incidence of adverse pregnancies, current treatment options are limited. Accordingly, research has shifted to the development of gene therapy technologies that provide targeted delivery of “payloads” to the placenta while limiting maternal and fetal exposure. This review describes the current strategies, including placental targeting peptide-bound liposomes, nanoparticle or adenovirus constructs decorated with specific peptide sequences and placental gene promoters delivered via maternal IV injection, directly into the placenta or the uterine artery, as well as noninvasive site-selective targeting of regulating genes conjugated with microbubbles via contrast-enhanced ultrasound. The review also provides a perspective on the effectiveness of these technologies in various animal models and their practicability and potential use for targeted placental delivery of therapeutics and genes in adverse human pregnancies affected by placental dysfunction.
- Published
- 2021